Exelixis Inks Third Collaboration Deal in a Week, This Time with Catalent

In its third collaboration deal this week, Exelixis has inked a licensing agreement with Catalent to gain access to three of Catalent’s target programs with antibody and ADC candidates, the companies announced Thursday.